Adding Albumin to Risk Score Improves Mortality Prediction
In patients undergoing transcatheter aortic valve replacement, low albumin tied to higher mortality
The effect was especially pronounced when questionnaires indicated depression both before and 6 months after aortic valve replacement; some question whether the finding can be clinically useful.Medscape Medical News
We thank Dr Sadaghianloo and colleagues for their comments on an important consideration in using cryopreserved tissue. Anytime allograft tissue is implanted, whether for aortic valve replacement, peripheral bypass, or creation of an access fistula, there is a risk of allogeneic sensitization of the host. The implications of allosensitization may be to increase transplant waitlist time and also to make post-transplantation management more challenging, but many of the patients in our study were not candidates for a kidney transplant.
Conclusions: The mitral valve simulation can help the surgeon understand valve behaviour and anticipate the outcome of a procedure.
Abstract BackgroundTranscatheter, bilateral branch pulmonary artery (PA) valve implantation is a novel treatment for patients with severe pulmonary insufficiency and oversized right ventricle (RV) outflow tract. There is scarce data on efficacy and safety of this approach. MethodsThis was a retrospective study of 8 patients with repaired tetralogy of fallot (TOF) who underwent bilateral branch PA valve implantation. Demographics, echocardiography, cardiac catheterization, and axial imaging data were reviewed. Variables were compared by a paired sample t‐test. ResultsAll patients were adult sized (weight 43–99 kg) w...
We describe a patient with coronary artery disease, mechanical aortic valve replacement, and reduced left ventricular function with recurrent ICD shocks. Despite medical treatment with beta-blocker and amiodarone, and after successful ablation of different VT morphologies in combination with substrate modification, ES could not be controlled. We performed renal denervation (RDN) to reduce arrhythmic burden. Thereafter, patient remained free from sustained and non-sustained VTs at 6-month follow-up.
Conclusions Major morbidity and mortality rates SCA-TAVR are equivalent to TF-TAVR. The SCA should be the preferred secondary access site for TAVR because it offers procedural and clinical outcomes comparable to TF-TAVR and applies to most patients who are not TF candidates.
Conclusions When femoral access is not feasible, DA access allows effective delivery of the valve but incurs an increased risk of death and adverse events, potentially the result of procedural differences.
Conclusions The LivaNova Mitroflow valve appears to be prone to early deterioration. Smaller size prostheses should be used cautiously and avoided with patient-prosthesis mismatch. The DL model anticalcification treatment seems unable to prevent early degeneration, and possibly contributes to even earlier failure.
Patients with symptomatic severe aortic stenosis and severe mitral regurgitation (SMR) or severe tricuspid regurgitation (STR) were excluded from the major transcatheter aortic valve replacement (TAVR) trials. We studied these 2 subgroups in patients at extreme risk for surgery in the prospective, non-randomized, single-arm CoreValve US Expanded Use Study.
Conclusion: Post-TAVR nadir platelet count can be predicted based on baseline and procedural data. Old age and GA contribute to clinically significant TP.Cardiology 2018;139:151-158